Regulators in the United States approved a new Alzhiemer's drug, targeting the underlying causes of the brain disease.
It comes after disregarded warnings from independent advisors that the much-debated treatment has not been shown to help slow the brain-destroying disease.
The Food and Drug Administration says the drug's ability to reduce harmful clumps of plaque in the brain is expected to slow dementia.